医学
临床试验
免疫疗法
肺癌
重症监护医学
肿瘤科
毒性
癌症
内科学
作者
Maria Lucia Reale,Gianpiero Romano,Loretta Paolelli,Angelo Di Leo
标识
DOI:10.1016/j.critrevonc.2023.104056
摘要
Immune checkpoint inhibitors (ICIs) have revolutionized lung cancer management improving overall survival and providing durable responses with a favorable toxicity profile. New questions have emerged regarding the efficacy and safety of immunotherapy among older adults, typically underrepresented in clinical trials. Several factors have to be taken into account in order to reduce the realistic risk of over or under-treatment of this growing subgroup of patients. In this perspective, geriatric assessment and screening tools should be implemented in clinical practice; moreover older patients' inclusion into adapted-designed clinical trials should be promoted. In this review, we discuss immunotherapy activity in advanced non-small cell lung cancer (NSCLC) older patients, the role of the comprehensive geriatric assessment, treatment toxicity and its management with a focus on future perspectives in this rapidly evolving scenario.
科研通智能强力驱动
Strongly Powered by AbleSci AI